Oncopeptides presents first interim data from the ongoing combination trial ANCHOR with melflufen at the 60th American Society of Hematology Meeting
Stockholm – December 1, 2018 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today a presentation of the first interim data with melflufen (Ygalo®) from the ongoing phase I/II study ANCHOR at the 60th ASH meeting in San Diego, California, USA.Overall conclusions · The combinations of melflufen and dexamethasone (dex) with either bortezomib or daratumumab in relapsed-refractory multiple myeloma (RRMM) patients are well tolerated · No dose limiting toxicity has been observed at the melflufen 30 and 40 mg dose levels in either regimens. The 40 mg dose level is still recruiting